Johnson & Johnson Consumer Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Johnson & Johnson Consumer Inc.
Positive Medtech Revenues Into H2, But M&A And IPOs May Wait
EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.
Dermatologist Survey Lacked Details, Choices To Support Neutrogena ‘#1 Recommended’ Claim
J&J failed to convince BBB National Program’s appeals panel a 2008 NAD decision supporting its “#1 dermatologist recommended” claim for Neutrogena should preclude another review. Panel says market has changed in 12 years since review of Unilever challenge and L’Oreal could make its own challenge.
Rx-360 Issues Guide On Remote Supplier Audits; CEO Warns They May Take Longer At First
Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.
- OTC, Consumer
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.